LOGIN  |  REGISTER
Chimerix

Verrica Pharmaceuticals (NASDAQ: VRCA) Stock Quote

Last Trade: US$5.92 0.27 4.78
Volume: 85,644
5-Day Change: 19.35%
YTD Change: -19.13%
Market Cap: US$251.130M

Latest News From Verrica Pharmaceuticals

NCE status provides a minimum of five years of regulatory exclusivity The Company’s U.S. patents and pending patent applications related to YCANTH™ are projected to expire between 2034 and 2041, excluding any patent term adjustment or patent term extension WEST CHESTER, Pa., March 26, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company... Read More
Reports YCANTH™ revenue of $1.9M for fourth quarter and $4.7M for full year 2023 Over 200 million lives now covered on commercial insurance and managed Medicaid plans Conference Call Scheduled for Today at 8:30 am ET WEST CHESTER, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical... Read More
WEST CHESTER, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that they will participate in a fireside chat at the TD Cowen 44 th Annual Healthcare Conference, which will be held in Boston, Massachusetts. Event details: Date: Tuesday,... Read More
WEST CHESTER, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, February 29, 2024 to provide a corporate update and discuss the Company's financial results... Read More
Lawsuit alleges false and misleading advertising and promotion of unapproved cantharidin-containing drugs by Dormer Laboratories in violation of federal and state law WEST CHESTER, Pa., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or, the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it... Read More
WEST CHESTER, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the Centers for Medicare & Medicaid Services (CMS) has issued a permanent J-Code (J7354) for YCANTH™, which is the only FDA-approved treatment for molluscum contagiosum.... Read More
There are approximately 3-4 million diagnoses of basal cell carcinomas in the U.S. each year, with a high unmet need for new treatment options Company reiterates lesion clearance data from Part 2 of Phase 2 expected in Q2 2024 WEST CHESTER, Pa., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring... Read More
WEST CHESTER, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it received the minutes from the Company’s recent Type C meeting with the U.S. Food and Drug Administration (FDA), which was held on November 6, 2023, to discuss the Phase... Read More
WEST CHESTER, Pa., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it is growing its distribution network by entering into an agreement with Walgreen Co. (“Walgreens”) to distribute YCANTH™ through its specialty pharmacy. Walgreens joins... Read More
WEST CHESTER, Pa., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that its development and commercialization partner, Torii Pharmaceutical Co., Ltd. (“Torii”), reported positive top-line results from its Phase 3 trial of TO-208 (referred to... Read More
WEST CHESTER, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced Ted White, Verrica President & Chief Executive Officer, will present at the upcoming Jefferies Global Healthcare Conference, which is being held in London from November 14-16,... Read More
Strong awareness and interest in prescribing YCANTH™ among dermatologists and pediatricians Over 112 million lives covered to date on commercial insurance and managed Medicaid plans Conference Call Scheduled for Today at 8:30 am ET WEST CHESTER, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring... Read More
WEST CHESTER, Pa., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, November 9, 2023, to provide a corporate update and discuss the Company's financial results... Read More
WEST CHESTER, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a virtual KOL event discussing the approval of YCANTH™ (cantharidin) topical solution for the treatment of molluscum contagiosum on Wednesday, October 11,... Read More
WEST CHESTER, Pa., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that that Ted White, Verrica President and CEO, will participate in a fireside chat at the H.C. Wainwright 25 th Annual Global Investment Conference on Tuesday, September 12,... Read More
YCANTH™ is the first and only FDA-approved treatment for molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children FFF Enterprises is Verrica’s exclusive distribution partner for YCANTH™ WEST CHESTER, Pa., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics... Read More
Verrica’s product YCANTH™ is the first and only FDA-approved treatment for molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children YCANTH™ is expected to be available for commercial use by licensed healthcare providers by September 2023 WEST CHESTER, Pa., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the... Read More
Presentation highlights the antitumor response of VP-315 for the non-surgical treatment of Basal Cell Carcinoma (BCC) as determined by clinical and histological lesion clearance There are approximately 3-4 million diagnoses of basal cell carcinomas in the U.S. each year, with a high unmet need for non-surgical treatment options WEST CHESTER, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or... Read More
In July, FDA approved YCANTH™ for the treatment of molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children YCANTH™ launch expected by September 2023 Expanding Part 2 enrollment of ongoing Phase 2 trial of VP-315 in basal cell carcinoma to accelerate clinical development Secured $125 million debt facility to support launch of YCANTH™ Cash... Read More
WEST CHESTER, Pa., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc . (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the acceptance of an abstract that will feature clinical data from the Company’s ongoing Phase 2 study of VP-315 for the treatment of basal cell carcinoma (“BCC”). The... Read More
Verrica received $50M upon the close of the transaction; $75M of additional capital available in tranches based on the achievement of certain revenue milestones Proceeds from the transaction to support the commercialization of YCANTH™, which was approved by the FDA on July 21, 2023, for treatment of molluscum contagiosum WEST CHESTER, Pa., July 26, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the... Read More
Term loan facility would provide for up to $125M in non-dilutive capital; $50M immediately available to Company following close of the transaction, which is expected to occur by the end of this week YCANTH™ is now the first FDA-approved treatment for molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children Verrica to host investor... Read More
Molluscum, is a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children YCANTH™ is a drug-device combination product administered by a healthcare professional; Verrica plans to make YCANTH™ available by September 2023 Verrica to host investor conference call and webcast Monday at 8:30 a.m. ET WEST CHESTER, Pa., July 21, 2023 (GLOBE NEWSWIRE) -- Verrica... Read More
WEST CHESTER, Pa., May 31, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President & Chief Executive Officer, will present at the upcoming Jefferies Healthcare Conference, which is being held at the New York Marriot Marquis... Read More
WEST CHESTER, Pa., May 10, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President & Chief Executive Officer, will present at the upcoming RBC Capital Markets Global Healthcare Conference, which is being held at the... Read More
New Drug Application for YCANTH™ (VP-102) PDUFA Goal Date of July 23, 2023 - Potential to Become Only FDA-approved Therapy for Treatment of Molluscum Contagiosum Raised Gross Proceeds of $32.5 Million in February 2023 in an Underwritten Offering VP-315 Advanced into Part 2 of Phase 2 Trial in Basal Cell Carcinoma WEST CHESTER, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”)... Read More
WEST CHESTER, Pa., April 12, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or, the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the first patient has been dosed in Part 2 of a Phase 2 study evaluating the Company’s potentially first-in-class oncolytic peptide, VP-315, for the treatment of basal... Read More
WEST CHESTER, Pa., April 11, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced Ted White, Verrica President and CEO, will present at the 22 nd Annual Needham Virtual Healthcare Conference, which is being held from April 17-20, 2023. Event details : Date: Monday, April... Read More
New Drug Application for VP-102 assigned PDUFA goal date of July 23, 2023 VP-102 has potential to address the approximately six million patients in the U.S. with molluscum contagiosum Dosing of first patient in Part 2 of Phase 2 study of VP-315 for treatment of basal cell carcinoma expected in 2Q 2023 Raised gross proceeds of $32.5 million in secondary offering; pro forma cash and cash equivalents to fund planned operations... Read More
WEST CHESTER, Pa., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced Ted White, Verrica President and CEO, will participate in a fireside chat at The Cowen 43 rd Annual Health Care Conference, taking place from March 6 - 8, 2023, in Boston, MA. Event details :... Read More
Assigns PDUFA goal date of July 23, 2023 VP-102 (cantharidin 0.7% Topical Solution) could potentially be the first FDA-approved treatment for molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children WEST CHESTER, Pa., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics... Read More
WEST CHESTER, Pa., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the pricing of its underwritten offering of 750,000 shares of its common stock and pre-funded warrants to purchase 4,064,814 shares of common stock. The shares of common stock are being sold at a... Read More
Potential First FDA-approved Therapy for Treatment of Molluscum Contagiosum Prevalence of Over 6 Million Molluscum Contagiosum Patients in the U.S. Alone WEST CHESTER, Pa., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it has resubmitted the New Drug... Read More
Registration Stability Batch for VP-102 Completed and Placed on Stability Process Validation Batches Successfully Manufactured Verrica Reaffirms its Expected Q1 2023 NDA Resubmission for VP-102 WEST CHESTER, Pa., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced... Read More

COPYRIGHT ©2023 HEALTH STOCKS HUB